Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra efficacy study in ulcerative colitis
ISRCTN13017615Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in autoimmune colitis (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission. Started Oct 2025; status: recruiting.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ISRCTN13017615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13017615.